☆ 4.6 Article

ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol

BMJ OPEN (2022)

Related references

Note: Only part of the references are listed.

Article Immunology

ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients

Eleni Karakike et al.

Summary: This study investigated the effect of personalized immunotherapy on critically ill COVID-19 patients. The results showed that anakinra had a favorable clinical improvement in patients with features of MALS. However, the tocilizumab treatment group had a higher incidence of secondary infections.

JOURNAL OF INNATE IMMUNITY (2022)

Add to Collection

Article Immunology

IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19

Georgios Renieris et al.

Summary: ARDS in COVID-19 is associated with inflammation, and danger-associated molecular patterns play a role. Calprotectin is associated with suPAR. In an animal model, COVID-19 plasma induces inflammatory reactions in murine lung and intestines, and pre-treatment with anti-S100A8/A9 can attenuate lung inflammation. Inhibition of IL-1 receptor or IL-1 alpha can alleviate the inflammatory response.

JOURNAL OF INNATE IMMUNITY (2022)

Add to Collection

Article Critical Care Medicine

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial

Jozefien Declercq et al.

Summary: In this trial evaluating IL-1 and IL-6 blockade treatment in COVID-19 patients, it did not shorten the time to clinical improvement, and there were no significant differences in mortality rate and incidence of serious adverse events between the groups.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Evdoxia Kyriazopoulou et al.

Summary: The SAVE-MORE phase 3 study demonstrated the efficacy of anakinra, an IL-1 alpha/beta inhibitor, in patients with COVID-19 and high serum levels of soluble plasminogen activator receptor, showing significant reduction in clinical deterioration and decreased 28-day mortality.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: A case series

Arjan van Laarhoven et al.

Summary: This study found that treatment with interferon gamma in a subset of COVID-19 patients led to a rapid decrease in viral load, conversion of viral culture from positive to negative, and eventual recovery of four patients without signs of hyperinflammation.

MED (2021)

Add to Collection

Article Microbiology

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Evangelos J. Giamarellos-Bourboulis et al.

CELL HOST & MICROBE (2020)

Add to Collection

Article Medicine, General & Internal

Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis

Evdoxia Kyriazopoulou et al.

BMC MEDICINE (2017)

Add to Collection

Article Critical Care Medicine

Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome

Nikolaos Antonakos et al.

CRITICAL CARE (2017)

Add to Collection

Article Critical Care Medicine

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial

Bita Shakoory et al.

CRITICAL CARE MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

Add to Collection

Review Immunology

Sepsis: Current Dogma and New Perspectives

Clifford S. Deutschman et al.

IMMUNITY (2014)

Add to Collection

Review Infectious Diseases

Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach

Richard S. Hotchkiss et al.

LANCET INFECTIOUS DISEASES (2013)

Add to Collection

Article Critical Care Medicine

Reversal of Immunoparalysis in Humans In Vivo A Double-Blind, Placebo-controlled, Randomized Pilot Study

Jenneke Leentjens et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)

Add to Collection

Article Medicine, General & Internal

Effect of Empirical Treatment With Moxifloxacin and Meropenem vs Meropenem on Sepsis-Related Organ Dysfunction in Patients With Severe Sepsis A Randomized Trial

Frank M. Brunkhorst et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)

Add to Collection

Article Medicine, General & Internal

Intensive insulin therapy and pentastarch resuscitation in severe sepsis

Frank M. Brunkhorst et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.